✕
Free ₹200 worth HealthCash on app
Use HealthCash to order medicines, health products & much more
Eptifibatide
Confused about any medicine? Just ask Practo AIFREE
50000+ health queries resolved in last month
Chat with Practo AI on Whatsapp
Not finding what you need? Ask Practo AI
FREE
Chat with Practo AI on Whatsapp
Description
Eptifibatide is used for decreasing the risks of major and life-threatening events or new episodes of heart attacks in patients suffering from acute coronary syndrome (ACS). Acute coronary syndrome (ACS) is caused by a sudden reduction or blockage of blood flow to the heart, causing chest pain and heart attacks. This medicine is used in patients who are to be managed medically. It is also used for the reduction of life-threatening adverse events in patients undergoing percutaneous coronary intervention or stent placement procedures.
QUICK LINKS:
Side effects
Major & minor side effects for Eptifibatide
Abdominal pain and discomfort
Back pain
Bleeding from the bladder
Bleeding gums
Blood in urine
Bloody or tarry stools
Blurred vision
Constipation
Presence of blood in cough
Dizziness when getting up suddenly from a sitting position
Headache
Heavy menstrual bleeding
Paralysis
Unusual bleeding or bruising
Shortness of breath
Unusual tiredness or weakness
Pinpoint red spots on skin
Difficulty in swallowing
Fast/irregular heart beat
Severe skin rash and hives
Puffing or swelling of eyelids
Slurred speech
Inability to move the arms, legs, or facial muscle
Uses of Eptifibatide
What is it prescribed for?
Acute Coronary Syndrome
This medicine is used to decrease the risk of death and a new episode of a heart attack in patients suffering from an acute coronary syndrome, including patients who are to be managed medically and those undergoing percutaneous coronary intervention.
Percutaneous Coronary Intervention
This medicine is used to decrease the risk of death, a new episode of a heart attack, or a need for urgent intervention in patients undergoing percutaneous coronary intervention, including those undergoing stenting procedure.
Concerns
Commonly asked questions
Onset of action
The effect of this medicine can be observed immediately following an intravenous administration.Duration of effect
The effect of this medicine lasts for an average duration of 4 to 6 hours.Safe with alcohol?
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.Is it habit forming?
No habit-forming tendencies were reported.Usage in pregnancy?
This medicine is not recommended for use in pregnant women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the potential benefits and risks associated with the use of this medicine.Usage while breast-feeding?
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the potential benefits and risks associated with the use of this medicine.
Allergy
This medicine is not recommended for use in patients with a known allergy to eptifibatide or any other inactive ingredients present along with it.
Bleeding disorder
This medicine is not recommended for use in patients with a history of bleeding disorders due to blood coagulation issues (bleeding diathesis) or active abnormal bleeding within the previous 30 days due to the increased risk of worsening of the patient’s condition.
Severe hypertension
This medicine is not recommended for use in patients suffering from severe hypertension (high blood pressure levels more than 200/110 mm Hg) that is not adequately controlled using appropriate medication due to the increased risk of worsening of the patient’s condition.
Major surgery
This medicine is not recommended for use in patients who have undergone major surgery within the preceding 6 weeks due to the increased risk of worsening of the patient’s condition.
Stroke
This medicine is not recommended for use in patients with a history of stroke within the past 30 days or any history of hemorrhagic stroke (an emergency condition where blood vessels rupture within the brain) due to the increased risk of worsening of the patient’s condition.
GP IIb/IIIa inhibitor
This medicine is not recommended for use in patients receiving or patients about to receive other parenteral GP IIb/IIIa inhibitors since it may worsen the patient's condition.
Hemodialysis
This medicine is not recommended for use in patients who are undergoing dialysis or have a dependency on this procedure due to the increased risk of worsening of the patient’s condition.
Warnings for special population
Pregnancy
This medicine is not recommended for use in pregnant women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the potential benefits and risks associated with the use of this medicine.
Breast-feeding
This medicine is not recommended for use in breastfeeding women unless absolutely necessary. Your doctor will determine the best course of treatment after evaluating the potential benefits and risks associated with the use of this medicine.
General warnings
Other medicines
Eptifibatide may interact with many other medicines and may cause severe adverse effects. Hence, it is advised that you inform the doctor about all your current medicines including any herbs and supplements before beginning treatment with this medicine.
Use in children
This medicine is not recommended for use in patients less than 18 years of age since the safety and efficacy of use are not clinically established.
Use in elderly
This medicine should be used with caution and monitoring in elderly patients since the risk of severe adverse effects is significantly high.
Bleeding test
It is recommended to collect blood samples and test the possibility of unexpected bleeding before and during therapy with this medicine. Patients should always be monitored for signs and symptoms that could indicate unusual or unexpected bleeding.
Kidney diseases
This medicine should be used with caution in patients with kidney diseases due to the increased risk of severe adverse effects. Regular monitoring of kidney function tests is necessary while receiving this medicine. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.
Hypertension
This medicine should be used with caution and monitoring in patients suffering from hypertension (high blood pressure levels). Use is not recommended if the increase in blood pressure level is very high (severe hypertension) and the patient is not receiving appropriate therapy to correct the blood pressure level.
Surgery
This medicine is not recommended for use in patients who have undergone major surgery, injury, trauma, or any other medical emergency within the past 6 weeks. Inform your doctor in advance so that the dose regimen with this medicine can be appropriately adjusted.
Missed Dose
Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low.
Overdose
Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol
Description
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Instructions
Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine
Ubiquinone/Vitamin E
Dipyridamole
Celecoxib
Fluoxetine
Citalopram
Clopidogrel
Prasugrel
Warfarin
Ibuprofen
Diclofenac
Abciximab
Magnesium salicylate
Tenecteplase
Disease interactions
Disease
Information not available.
Food interactions
Information not available.
Lab interactions
Information not available.
This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. The dose strength and method of administration are likely to vary based on multiple criteria. You may be asked to frequently undertake certain tests before and during therapy with this medicine. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine.
Miscelleneous
How it works
This medicine prevents the abnormal formation of blood clots and associated adverse events.
Legal Status
Classification
Category
Glycoprotein platelet inhibitors
Schedule
Schedule H
[Internet]. 2018 [cited 27 September 2018]. Available from:
[Internet]. Mri.cts-mrp.eu. 2018 [cited 27 September 2018]. Available from:
[Internet]. Medicines.org.uk. 2018 [cited 27 September 2018]. Available from:
[Internet]. Accessdata.fda.gov. 2018 [cited 27 September 2018]. Available from:
DailyMed - Eptifibatide injection [Internet]. Dailymed.nlm.nih.gov. 2018 [cited 27 September 2018]. Available from:
Eptifibatide - DrugBank [Internet]. Drugbank.ca. 2018 [cited 27 September 2018]. Available from:
Information on this page was last updated on 28 Jan 2019
Disclaimer
We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.